PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27599706-4	2017	METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs.	Pioglitazone	181-193	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135	
22942318-6	2012	Use of this two-step statistical evaluation is illustrated with the examination of five drugs of varying capabilities to inactivate CYP3A4: ketoconazole, erythromycin, raloxifene, rosiglitazone, and pioglitazone.	Pioglitazone	199-211	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138	
26296069-1	2015	PURPOSE: Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates.	Pioglitazone	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64	
17214065-1	2006	BACKGROUND: Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes, metabolized mainly by CYP2C8 and CYP3A4.	Pioglitazone	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138	
18783297-9	2008	Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies.	Pioglitazone	116-128	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33	
17201456-6	2007	CYP2C8 and CYP3A4 are the main isoenzymes catalysing biotransformation of pioglitazone (as with troglitazone), whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8.	Pioglitazone	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17	
16867170-0	2006	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.	Pioglitazone	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48	
16283275-1	2005	OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4.	Pioglitazone	92-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-180	
16447051-10	2006	CONCLUSIONS: Pioglitazone does not increase the plasma concentrations of repaglinide, indicating that the inhibitory effect of pioglitazone on CYP2C8 and CYP3A4 is very weak in vivo, probably due to its extensive plasma protein binding.	Pioglitazone	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-160	
16867170-3	2006	The metabolism of pioglitazone by CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 was investigated using human recombinant CYP isoforms.	Pioglitazone	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97	
16867170-4	2006	In particular, the inhibitors of CYP2C8, but also those of CYP3A4, markedly inhibited the elimination of pioglitazone and the formation of M-IV by HLM.	Pioglitazone	105-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65	
16867170-9	2006	In conclusion, pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro.	Pioglitazone	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92	
16447051-0	2006	Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.	Pioglitazone	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56	
16447051-1	2006	OBJECTIVE: Pioglitazone, a thiazolidinedione antidiabetic, inhibits cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes in vitro.	Pioglitazone	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104	
15900286-1	2005	BACKGROUND AND OBJECTIVE: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P450 (CYP) 2C8 and CYP3A4 in vitro.	Pioglitazone	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140	
16372821-14	2005	CYP2C8 and CYP3A4 are the main enzymes catalysing biotransformation of the thiazolidinediones troglitazone and pioglitazone, whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8.	Pioglitazone	111-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17	
12642470-4	2003	While troglitazone was the most potent, rosiglitazone and pioglitazone generally exceeded troglitazone in absolute CYP3A4 activity achieved at concentrations > or =10 microM.	Pioglitazone	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121	
12642470-6	2003	Microarray analysis revealed rifampin > troglitazone > pioglitazone > rosiglitazone in terms of CYP3A4 mRNA induction potential with 10 microM compound.	Pioglitazone	61-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-111	
11921435-7	2002	Further differences in the safety profiles of these agents arise because the oxidative metabolism for each agent occurs by distinct cytochrome pathways: troglitazone and pioglitazone involve CYP 3A4 and CYP 2C8 whereas rosiglitazone is principally metabolized by CYP 2C8.	Pioglitazone	170-182	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-198	
11921435-8	2002	CYP 3A4 is involved in the metabolism of over 150 drugs, hence the potential for drug interactions with troglitazone and pioglitazone is much greater than with rosiglitazone.	Pioglitazone	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-7	
15900286-12	2005	CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metabolism in vivo in humans.	Pioglitazone	75-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51	
12463723-0	2002	Pioglitazone: effect on CYP3A4 activity.	Pioglitazone	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30	
12463723-1	2002	Clinical studies demonstrate CYP3A4 enzyme induction with troglitazone, a thiazolidinedione derivative structurally related to pioglitazone.	Pioglitazone	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35	
12463723-2	2002	The objective of this prospective, open-label study conducted in healthy volunteers was to evaluate the influence of multiple-dose pioglitazone therapy on the urinary excretion ratio of 6-beta-hydroxycortisol to cortisol, an endogenous marker of CYP3A4 activity.	Pioglitazone	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	246-252